News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
489,447 Results
Type
Article (8072)
Company Profile (144)
Press Release (481231)
Multimedia
Podcasts (6)
Webinars (6)
Section
Business (166752)
Career Advice (304)
Deals (25741)
Drug Delivery (7)
Drug Development (52943)
Employer Resources (14)
FDA (9763)
Job Trends (8577)
News (238244)
Policy (17905)
Tag
2025 Best Places to Work (5)
2026 Best Places to Work (12)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Digital (1)
2027 Pharm Country Standard (1)
Academia (502)
Accelerated approval (31)
ADA (18)
Adcomms (1)
Allergies (103)
Alliances (33158)
ALS (122)
Alzheimer's disease (1012)
Antibody-drug conjugate (ADC) (335)
Approvals (10493)
Artificial intelligence (381)
ASCO (160)
Autoimmune disease (258)
Automation (34)
Bankruptcy (264)
Belgium (4)
Best Places to Work (6961)
BIO (36)
Biologics (59)
BIOSECURE Act (1)
Biosimilars (126)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (29)
Bladder cancer (148)
Brain cancer (36)
Breast cancer (553)
Cancer (4121)
Cardiovascular disease (248)
Career advice (245)
Career pathing (1)
CAR-T (194)
CDC (2)
CDMO (36)
Celiac Disease (3)
Cell therapy (532)
Cervical cancer (37)
Clinical research (48637)
Collaboration (1380)
Commercialization (32)
Compensation (1662)
Complete response letters (36)
COVID-19 (795)
CRISPR (75)
C-suite (869)
Cystic fibrosis (89)
Data (6657)
Denatured (4)
Depression (110)
Dermatology (103)
Diabetes (387)
Diagnostics (4284)
Digital health (43)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (175)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (176)
Earnings (74404)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (240)
Events (89191)
Executive appointments (742)
Eye disease (6)
FDA (12733)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (21)
Frontotemporal dementia (25)
Funding (1007)
Gene editing (140)
Generative AI (15)
Gene therapy (358)
GLP-1 (344)
Government (957)
Grass and pollen (2)
Guidances (286)
Healthcare (9439)
Hematology (115)
HIV (60)
Huntington's disease (29)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (82)
Immunology and inflammation (114)
Immuno-oncology (75)
Indications (188)
Infectious disease (1003)
Inflammatory bowel disease (145)
Inflation Reduction Act (4)
Influenza (90)
Intellectual property (274)
Interviews (41)
IPO (12400)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (91)
Layoffs (59)
Legal (5195)
Licensing (62)
Liver cancer (47)
Longevity (28)
Lung cancer (586)
Lung diease (10)
Lymphoma (282)
Machine learning (30)
Management (3)
Manufacturing (628)
Marketing (24)
MASH (137)
Medical affairs (2)
Medical device (8730)
Medtech (8930)
Mergers & acquisitions (14487)
Metabolic disorders (804)
mRNA (80)
Multiple sclerosis (118)
Multispecific (3)
NASH (4)
Netherlands (4)
Neurodegenerative disease (247)
Neuropsychiatric disorders (41)
Neuroscience (1984)
Neurotech (2)
NextGen: Class of 2026 (3153)
Non-profit (845)
Obesity (256)
Opinion (11)
Ovarian cancer (184)
Pain (195)
Pancreatic cancer (235)
Parkinson's disease (219)
Partnered (12)
Patents (530)
Patient advocacy (3)
Patient recruitment (550)
Patient selection (55)
Peanut (34)
People (41567)
Peptides (23)
Pharmaceutical (30)
Pharmacy benefit managers (11)
Phase 1 (15715)
Phase 2 (21767)
Phase 3 (14676)
Pipeline (8908)
Policy (20)
Postmarket research (1570)
Preclinical (6620)
Press Release (34)
Prostate cancer (211)
Psychedelics (12)
Radiopharmaceuticals (205)
Rare diseases (637)
Real estate (3026)
Recruiting (6)
Regenerative medicine (18)
Regulatory (15250)
Reports (24)
Research institute (597)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (51)
Schizophrenia (111)
Series A (179)
Series B (129)
Service/supplier (5)
Sickle cell disease (69)
Special edition (1)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2021)
Stem cells (3)
Stomach cancer (3)
Substance use disorders (20)
Supply chain (56)
Switzerland (2)
Tariffs (2)
The Weekly (2)
Vaccines (365)
Venture capital (19)
Weight loss (88)
Wet AMD (3)
Women's health (101)
Date
Today (170)
Last 7 days (821)
Last 30 days (2317)
Last 365 days (19216)
2026 (17029)
2025 (19259)
2024 (22998)
2023 (26542)
2022 (34590)
2021 (37184)
2020 (33479)
2019 (23256)
2018 (17468)
2017 (18766)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (232)
Alabama (80)
Alaska (2)
Arizona (329)
Arkansas (12)
Asia (18103)
Australia (2128)
California (13298)
Canada (3434)
China (593)
Colorado (549)
Connecticut (466)
Delaware (234)
Europe (24862)
Florida (1980)
Georgia (418)
Hawaii (3)
Idaho (46)
Illinois (797)
India (66)
Indiana (339)
Iowa (19)
Japan (465)
Kansas (105)
Kentucky (34)
Louisiana (30)
Maine (27)
Maryland (1313)
Massachusetts (8717)
Michigan (325)
Minnesota (622)
Mississippi (5)
Missouri (86)
Montana (20)
Nebraska (11)
Nevada (138)
New Hampshire (61)
New Jersey (2927)
New Mexico (12)
New York (3112)
North Carolina (1409)
North Dakota (4)
Northern California (6748)
Ohio (311)
Oklahoma (15)
Oregon (17)
Pennsylvania (2483)
Puerto Rico (24)
Rhode Island (32)
South America (407)
South Carolina (81)
South Dakota (1)
Southern California (5563)
Tennessee (130)
Texas (2193)
United States (43054)
Utah (404)
Vermont (1)
Virginia (169)
Washington D.C. (39)
Washington State (1015)
West Virginia (1)
Wisconsin (83)
Wyoming (1)
489,447 Results for "altimmune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
Having linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.
November 10, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Altimmune to Participate in Stifel Cardiometabolic Forum
September 23, 2026
·
1 min read
GLP-1
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among others, in this space.
July 28, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
November 5, 2026
·
1 min read
Press Releases
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
November 10, 2026
·
10 min read
Press Releases
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 3, 2026
·
1 min read
Press Releases
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
October 27, 2026
·
7 min read
Press Releases
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
October 19, 2026
·
5 min read
Press Releases
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
August 12, 2026
·
11 min read
Press Releases
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
November 6, 2026
·
4 min read
1 of 48,945
Next
